Treatments, which will be administered at seven clinical sites across the US have commenced.
Declan Daly, CEO of Isolagen, said: “Concerning our pivotal clinical program on wrinkle correction, we expect to review the six month efficacy data on our Phase III study of the Isolagen therapy prior to September 1, 2008. We have focused our resources to meet the goals of advancing this program and our acne program and we are attempting to raise additional funding.”